Integrated Traditional Chinese and Western Medicine Oncology

The Department of Integrated Traditional Chinese and Western Medicine Oncology of Tianjin People's Hospital, formerly the Oncology Department of the Second Central Hospital, has been established for nearly 50 years. Since its establishment, through the hard work of all staff, the Oncology Department has continued to grow and develop, and has always maintained its advanced status and social influence in the country. The department currently has 98 beds and 42 medical staff, including 16 doctors and 26 nursing staff. Physicians: 2 chief physicians, 2 deputy chief physicians, 6 attending physicians, and 6 residents, including 4 masters and 1 doctor. The Oncology Department has Li Weilian, a well-known expert who enjoys special allowances from the State Council, as the chief director of the department, subject leader, and doctoral supervisor. He has high medical ethics and superb medical skills. He was awarded the title of "People's Good Doctor" by the Ministry of Health and called on all medical workers to learn from him. Specializes in comprehensive treatment of malignant tumors through radiotherapy, chemotherapy, traditional Chinese medicine and other integrated traditional Chinese and Western medicine. Yao Qiang is the director of the Department of Oncology and a master's tutor. He is good at integrated treatment of traditional Chinese and Western medicine such as chemotherapy for malignant tumors and traditional Chinese medicine. He also has rich experience in the diagnosis and treatment of breast hyperplasia and other diseases. Wang Fengwei, director of the Radiotherapy Center, has a doctorate in the United States. He has comprehensive theoretical knowledge and rich clinical experience in radiotherapy for malignant tumors. Qin Yukun, deputy chief physician, specializes in radiotherapy and chemotherapy for malignant tumors of the head and neck.Oncologists mainly use new concepts and results of surgery, radiotherapy, chemotherapy and other methods to scientifically formulate standardized and individualized comprehensive treatment plans based on the patient's physical condition, tumor pathological type, stage, extent of infiltration, biomolecular markers, and lesion development trends. He has rich clinical experience in the diagnosis and treatment of malignant tumors such as gastrointestinal tumors and head and neck cancer. In particular, the treatment of complications of advanced tumors and cancer pain also follows the latest international treatment concepts and methods, striving to minimize patient pain, improve patients' quality of life, and extend survival time. Comprehensive treatment of traditional Chinese and Western medicine is one of the characteristics of the oncology department. The application of traditional Chinese medicine combined with radiotherapy and chemotherapy can achieve the effect of reducing toxicity and increasing effectiveness. For patients with adverse reactions such as acute enteritis, dry mouth after radiotherapy, decreased saliva, bone marrow suppression, and physical decline during radiotherapy and chemotherapy, different Chinese medicines are used to reduce the toxic and side effects of radiotherapy and chemotherapy. It has received good results. It has improved the patient's tolerance and continuity of treatment to a certain extent, shortened the treatment cycle, and reduced the cost of treatment. The use of traditional Chinese medicine methods of soothing the liver and regulating qi, activating blood circulation and removing blood stasis, and softening and dispersing stagnations has obvious effects on breast hyperplasia.At present, the oncology department has a complete set of the latest imported American Varian 21EX linear accelerator, Eclipse three-dimensional external beam treatment planning system, multi-leaf grating and related quality verification systems, as well as a CT simulation positioning machine and a conventional X-ray simulation positioning machine, which can implement the most advanced treatments in the field of tumor treatment today. The Department of Oncology also has very rich experience in clinical trials of new drugs, and has participated in more than ten international and domestic clinical new drug trials. The experimental drugs include: Rituximab, Letrozole, Topotecan, Taxotere, YH-16 (Endo), etc. Over the years, the department has adhered to the scientific outlook on development, strived to provide humanized services, and provided optimal treatment plans for cancer patients. The department has won the title of National Youth Civilization at the ministerial level and has also been praised by the majority of patients.